Actively Recruiting

Phase 1
Age: 18Years +
All Genders
Healthy Volunteers
NCT05802329

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

Led by Ocugen · Updated on 2025-12-03

24

Participants Needed

5

Research Sites

132 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema

CONDITIONS

Official Title

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Type 1 or Type 2 Diabetes Mellitus
  • Decreased visual acuity primarily due to diabetic macular edema
  • Central-involved diabetic macular edema with specific central retinal subfield thickness values measured by SD-OCT
  • Best corrected visual acuity between 24 and 78 letters on ETDRS chart
  • Clear enough ocular media and ability to cooperate for good quality retinal imaging
  • No prior anti-VEGF injection or at least 2 consecutive anti-VEGF injections with incomplete resolution of retinal thickness within 1 year
  • Last anti-VEGF injection at least six weeks (45 days) before study treatment in the study eye
Not Eligible

You will not qualify if you...

  • Any condition preventing clear view of retina (e.g., significant cataract, vitreous hemorrhage)
  • Uncontrolled hypertension
  • Uncontrolled glaucoma
  • Other eye diseases in the study eye aside from center-involved diabetic macular edema
  • Intravitreal or periocular steroid treatment within 3 months before screening
  • Any eye surgery within 3 months before screening in the study eye
  • Poorly controlled diabetes (HbA1c ≥ 10%)
  • History of retinal detachment or other retinal vascular disease in the study eye
  • Focal or pan-retinal laser treatment within 3 months before screening in the study eye
  • Presence of inherited retinal disease or history of proliferative diabetic retinopathy
  • History of kidney disease including stage 3b or worse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Advanced Research LLC

Deerfield Beach, Florida, United States, 33064

Actively Recruiting

2

Erie Retina Research, LLC

Erie, Pennsylvania, United States, 16507

Actively Recruiting

3

Retina Consultants of Texas Research Centers

Bellaire, Texas, United States, 77401

Actively Recruiting

4

Retina Consultants of America

Southlake, Texas, United States, 76092

Actively Recruiting

5

Gundersen Health System

La Crosse, Wisconsin, United States, 54601

Actively Recruiting

Loading map...

Research Team

R

Roshan A George, MD, MPH

CONTACT

O

Oscar Cuzzani, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here